These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26644956)

  • 1. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d.
    McIntyre RS; Fayyad RS; Guico-Pabia CJ; Boucher M
    Prim Care Companion CNS Disord; 2015; 17(3):. PubMed ID: 26644956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
    Thase ME; Fayyad R; Cheng RF; Guico-Pabia CJ; Sporn J; Boucher M; Tourian KA
    Curr Med Res Opin; 2015 Apr; 31(4):809-20. PubMed ID: 25758058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.
    Boyer P; Vialet C; Hwang E; Tourian KA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
    Clayton AH; Tourian KA; Focht K; Hwang E; Cheng RF; Thase ME
    J Clin Psychiatry; 2015 May; 76(5):562-9. PubMed ID: 25375652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression.
    Zilcha-Mano S; Wang X; Wajsbrot DB; Boucher M; Fine SA; Rutherford BR
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):579-584. PubMed ID: 34183490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT
    J Clin Psychiatry; 2013 Oct; 74(10):1010-7. PubMed ID: 24229754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
    Katzman MA; Nierenberg AA; Wajsbrot DB; Meier E; Prieto R; Pappadopulos E; Mackell J; Boucher M
    J Clin Psychopharmacol; 2017 Oct; 37(5):555-561. PubMed ID: 28817491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
    Kornstein SG; Guico-Pabia CJ; Fayyad RS
    Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.
    McIntyre RS; Fayyad RS; Guico-Pabia CJ; Boucher M
    Prim Care Companion CNS Disord; 2015; 17(1):. PubMed ID: 26137355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.